CADS: The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes

Sponsor
Walter Reed National Military Medical Center (U.S. Fed)
Overall Status
Completed
CT.gov ID
NCT01648244
Collaborator
(none)
28
1
1
36
0.8

Study Details

Study Description

Brief Summary

The primary purpose of this study is to determine whether the use of CADS by primary care providers (PCPs) for their patients with type 2 diabetes (T2DM) changes the quality of care relative to a "usual care" group in terms of objective outcome measures of glycemic control (e.g., A1c, mean blood glucose, frequency of hypoglycemic episodes) and in terms of subjective ratings by patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Computer-Assisted Decision Support
N/A

Detailed Description

The CADS software integrates the patient's home blood glucose data with appropriate laboratory data (e.g. A1c, liver function, kidney function), demographic data (age, gender), current and previous medications, and active/inactive medical diagnoses. The software makes a recommendation about what medication changes are appropriate with potential alternates. Providers with their patients are block randomized into CADS or "Usual Care" for 1 year.

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Use of a Computer Assisted Diabetes Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes Who Are Treated by Primary Care Providers
Study Start Date :
Mar 1, 2012
Actual Primary Completion Date :
Mar 1, 2015
Actual Study Completion Date :
Mar 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Computer-Assisted Decision Support

These providers will use the CADS program to treat their enrolled patients.

Other: Computer-Assisted Decision Support
The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either "accept" or "reject" the recommendation by the software.Providers with their patients are block randomized into CADS or "Usual Care" for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting "usual care" will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year.

Outcome Measures

Primary Outcome Measures

  1. Change in A1c [baseline, 12, 24, 36, and 48 months]

    Change is A1c will be measured 5 times over the course of the study to compare the patients for whom the provider is using CADS to those patients whose providers are delivering "usual care".

Secondary Outcome Measures

  1. Major events [ongoing]

    The number of major ("severe") hypoglycemic events whether subjective (undocumented) or objective (SMBG or other confirmation, need for intervention, seizure, coma), and emergency room visits for DM-related causes.

  2. Other DM-related events [ongoing]

    Number of ER visits for DM-related causes, DM-related hospitalizations and hospital days, and DM-related clinic visits.

  3. Glucose measures [baseline, 12, 24, 36, 48 months]

    Mean pre-prandial glucose, mean post-prandial glucose, post-prandial glucose excursions

  4. Blood pressure [baseline, 12, 24, 36, and 48 months]

    Clinically significant or statistically detectable changes in BP

  5. Lipids [baseline, 12, 24, 36, and 48 months]

    Clinically significant or statistically detectable changes in lipid profile.

  6. Patient satisfaction with treatment [basline and 48 months]

    Clinically significant or statistically detectable changes in satisfaction with treatment as measured by the DTSQ.

  7. Quality of life [baseline and 48 months]

    Clinically significant or statistically detectable changes in quality of life for patients with DM as measured by the SF-8.

  8. Degree of Acceptance [baseline and 48 months]

    The degree of acceptance of CADS by PCPs as measured by a technical assessment questionnaire.

  9. Acceptance of uploading data [baseline, 12, 24, 36, and 48 months]

    The degree of acceptance of uploading the glucose meters by patients as measured by a technical assessment questionnaire.

  10. Demographic variables [baseline and 48 months]

    The relationship of the primary and/or secondary outcomes to the type of provider, board-certification or eligibility, years in practice, age and gender.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Non-specialist physician (general internist or family practitioner), nurse practitioner, physicians assistant

  • Absence of orders for deployment or permanent change of station

  • Willingness to recruit up to 19 patients prior to randomization

  • Willingness to deliver "usual care" as defined in Section 6.3.2 of the protocol.

Exclusion Criteria:
  • Specialist physicians

  • Orders for deployment or permanent change of station

  • Unwillingness to recruit up to 19 patients prior to randomization

  • No prior experience with management of type 2 diabetes in adults

  • Unwillingness to deliver "usual care" as defined in Section 6.3.2 of the protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Walter Reed National Military Medical Center Bethesda Maryland United States 20889

Sponsors and Collaborators

  • Walter Reed National Military Medical Center

Investigators

  • Principal Investigator: Robert A Vigersky, M.D., Walter Reed National Military Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Alicia L. Warnock, Director, Diabetes Institute, Walter Reed National Military Medical Center
ClinicalTrials.gov Identifier:
NCT01648244
Other Study ID Numbers:
  • 353757
First Posted:
Jul 24, 2012
Last Update Posted:
Nov 25, 2015
Last Verified:
Nov 1, 2015
Keywords provided by Alicia L. Warnock, Director, Diabetes Institute, Walter Reed National Military Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 25, 2015